Loading...
XKRX
048410
Market cap181mUSD
Jul 25, Last price  
6,320.00KRW
1D
-6.78%
1Q
-42.60%
Jan 2017
19.25%
IPO
-45.52%
Name

Hyundai Bioscience Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
16.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.04%
Rev. gr., 5y
-12.94%
Revenues
15.05b
+58.73%
37,079,377,95025,538,238,61028,912,613,04040,674,617,76736,101,390,15131,970,192,87831,235,879,55630,085,994,56212,511,415,7769,241,494,4997,851,578,1079,481,384,63015,050,025,350
Net income
-6.93b
L-52.21%
-7,957,931,030-9,499,039,850-1,323,340,710711,285,387-8,070,237,1771,218,194,2382,617,921,261767,215,168-8,259,902,290-20,051,086,939-15,807,267,634-14,499,357,710-6,929,528,500
CFO
2.26b
P
-7,870,646,550-9,177,527,770-302,743,800-269,235,163-4,917,424,882-4,181,286,3334,660,144,3028,897,521,6977,242,854,964-748,134,495-16,765,912,393-6,008,318,9202,257,053,800
Dividend
Dec 29, 2003100 KRW/sh
Earnings
Aug 12, 2025

Profile

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.
URL
http://www.hyundaibioscience.com/
IPO date
Aug 08, 2002
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
15,050,025
58.73%
9,481,385
20.76%
7,851,578
-15.04%
Cost of revenue
9,599,266
14,265,384
25,183,210
Unusual Expense (Income)
NOPBT
5,450,759
(4,784,000)
(17,331,632)
NOPBT Margin
36.22%
Operating Taxes
1,044
(805,474)
Tax Rate
NOPAT
5,450,759
(4,785,044)
(16,526,157)
Net income
(6,929,528)
-52.21%
(14,499,358)
-8.27%
(15,807,268)
-21.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
139,964
1,094,092
3,596,284
BB yield
-0.02%
-0.11%
-0.33%
Debt
Debt current
26,272,864
5,514,103
6,207,245
Long-term debt
1,081,548
178,967
83,396
Deferred revenue
Other long-term liabilities
459,040
541,557
665,690
Net debt
23,697,810
(8,759,961)
(14,938,261)
Cash flow
Cash from operating activities
2,257,054
(6,008,319)
(16,765,912)
CAPEX
(169,575)
(587,536)
(1,543,615)
Cash from investing activities
(19,740,413)
5,177,464
8,517,586
Cash from financing activities
19,189,607
(57,966)
1,895,335
FCF
4,750,471
(128,357)
(8,730,956)
Balance
Cash
3,656,602
11,811,880
18,732,425
Long term investments
2,641,151
2,496,477
Excess cash
2,904,101
13,978,962
20,836,323
Stockholders' equity
338,103
7,350,585
(42,055,448)
Invested Capital
66,152,753
44,008,519
107,205,469
ROIC
9.90%
ROCE
8.20%
EV
Common stock shares outstanding
42,229
39,776
39,367
Price
14,110.00
-45.94%
26,100.00
-4.74%
27,400.00
8.51%
Market cap
595,856,538
-42.60%
1,038,152,869
-3.76%
1,078,668,788
15.72%
EV
619,554,348
1,029,392,908
1,063,730,526
EBITDA
6,084,577
(3,349,058)
(15,549,397)
EV/EBITDA
101.82
Interest
2,312,982
314,573
448,653
Interest/NOPBT
42.43%